Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

Gonzalez V.H., Berger B., Goldberg R., Gordon C.M., Khurana R.N., Angeles R., Shams N.

2021
Translational vision science & technology

View publication

Therapeutic Area

Back of the eye (BOTE)
Categories

Clinical development

Affiliations

Valley Retina Institute, TX, McAllen, United States; Retina Research Center, TX, Austin, United States; Bay Area Retina Associates, CA, United States; MI, Jackson, United States; Northern California Retina Vitreous Associates, Mountain View, CA, United States; Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA; Santen USA, Emeryville, CA, USA; ProQR Therapeutics NV, MA, Cambridge, United States

Related Publications

Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective

Shi-van Wielink K., Dahlmann-Noor A., Li J., de Milliano T.W.L., Ernst F., Croci F., Sharma Y., Punekar Y.

Two-year prospective natural history study of EYS-associated retinitis pigmentosa using adaptive optics: the KEYS study

Masakazu H., Akiko M., Midori Y., Elena G.-S., Shohei K., Satoshi Y., Yuki T., Masanao T., Shuhei K., Yasuhiko H., Yasuo K., Kiyoko G.

Prospective natural history and clinical biomarkers of EYS-associated retinopathy in the KEYS study

Taniguchi M, Togashi Y, Yokota S, Hiraoka M, Kitahata S, Nakamura N, Yamamoto M, Mandai M, Gocho K, Toshimori M, Hirami Y, Gomi F, Kurimoto Y, Maeda A.

View all Back of the eye (BOTE) publications